Reuters India |
A respiratory expert undermines GSK's case for new asthma drug mepolizumab
FierceBiotech Investigators for GlaxoSmithKline ($GSK) detailed their promising Phase III data for the IL-5 biologic mepolizumab in asthma today, noting that the injectable halved the rate of exacerbations among a group of patients with uncontrolled cases of the … UPDATE 1-Cost a focus as GSK takes lead in new wave of biotech lung drugs |
View full post on asthma – Google News